Pharmaceutical companies are backing away from a growing threat that could kill 10 million people a year by 2050

Just two years after Novartis announced it would embrace the challenge of searching for cures for life-threatening infections known as superbugs, the drugmaker said last week it would exit antibacterial and antiviral research.

https://www.businessinsider.com.au